An estimated 88 million American adults — roughly one in three — have insulin resistance. Most have no idea. Their fasting glucose may be normal. Their A1c may be normal. Nothing on their standard lab work raises a flag. And yet, silently, their cardiovascular risk is accumulating at a rate that their apparent health profile does not suggest.
Insulin resistance is not a single discrete disease. It is a physiological state in which cells throughout the body — particularly in skeletal muscle, liver, and adipose tissue — become progressively less responsive to insulin signaling. The pancreas compensates by producing more insulin. For a period that can last years or decades, blood glucose remains normal — but fasting and postprandial insulin levels are elevated, quietly driving a cascade of metabolic changes that accelerate atherosclerosis.
As a cardiologist, I think about insulin resistance constantly — not because it's a diabetes problem, but because it's a cardiovascular problem that begins long before diabetes develops.
The Mechanism: How Insulin Resistance Harms the Heart
Insulin resistance doesn't damage the heart through a single pathway. It operates through multiple simultaneous mechanisms:
Dyslipidemia of insulin resistance
Elevated insulin stimulates hepatic VLDL production, increasing triglycerides. This drives a shift in LDL particle distribution toward smaller, denser, more atherogenic particles — without necessarily changing LDL-C. ApoB rises while LDL-C appears normal. HDL falls. This lipid pattern is one of the most atherogenic in clinical medicine.
Endothelial dysfunction
Hyperinsulinemia impairs nitric oxide production in the endothelium — the single-cell layer lining every blood vessel. Nitric oxide normally causes vasodilation and protects against atherosclerosis initiation. When it's reduced, the endothelium becomes "sticky," promotes platelet aggregation, and loses its primary anti-atherogenic function.
Chronic low-grade inflammation
Visceral adipose tissue — the metabolically active fat that accumulates around the abdominal organs — secretes pro-inflammatory cytokines including TNF-alpha, IL-6, and resistin. These promote arterial wall inflammation, endothelial activation, and the oxidative modification of LDL particles that initiates plaque formation.
Hypertension
Insulin resistance increases sympathetic nervous system activity and promotes renal sodium retention, driving blood pressure upward. Elevated insulin also directly stimulates smooth muscle cell proliferation in arterial walls, contributing to arterial stiffening.
Prothrombotic state
Insulin resistance elevates plasminogen activator inhibitor-1 (PAI-1), impairing fibrinolysis and creating a pro-clotting environment. Combined with endothelial dysfunction and platelet hyperreactivity, this dramatically increases the risk that vulnerable plaque will rupture and cause an acute coronary event.
Why Standard Labs Miss It
The standard metabolic panel checks fasting glucose and, if ordered, hemoglobin A1c. Both measure the downstream effects of insulin resistance — elevated blood sugar — not insulin resistance itself. By the time fasting glucose reaches the prediabetic range (100–125 mg/dL), insulin resistance has typically been present for years or decades. The pancreatic beta cells have been working overtime to compensate, and early atherosclerosis may already be under way.
The Diagnostic Gap
A patient with fasting glucose of 92 mg/dL (technically "normal"), triglycerides of 190, HDL of 38, blood pressure of 132/84, and a waist circumference of 38 inches has multiple features of insulin resistance — but nothing on their standard lab work would trigger intervention. Every individual marker is either normal or "borderline." Together, they represent a high-risk metabolic pattern.How to Actually Detect Insulin Resistance
The gold standard for measuring insulin resistance is the hyperinsulinemic-euglycemic clamp — a complex research procedure not suitable for clinical practice. In real-world cardiology, several accessible markers can be used in combination:
Clinical Markers of Insulin Resistance
The triglyceride/HDL ratio is one of the most practical and underused proxies for insulin resistance and small dense LDL. A ratio above 3.0 in a fasting sample is a strong signal that warrants further evaluation. A ratio above 5.0 is associated with a high probability of small dense LDL pattern — the most atherogenic lipid phenotype.
Insulin Resistance and the Lipid Panel: The Hidden Disconnect
This is where insulin resistance becomes directly relevant to cardiovascular risk assessment. A patient with insulin resistance can have an LDL-C of 105 mg/dL — within normal range — while carrying an ApoB of 125 mg/dL and an LDL particle number in the highest quartile. Their atherogenic particle burden is high. Their standard panel says otherwise.
This discordance between LDL-C and particle burden is not a statistical anomaly — it is a predictable consequence of insulin resistance physiology. It is one of the primary reasons I measure ApoB in every patient: in an insulin-resistant population (which describes a significant fraction of adults over 40), LDL-C routinely underestimates atherogenic exposure.
Metabolic Syndrome: Insulin Resistance Made Official
Metabolic syndrome is the clinical codification of insulin resistance. A diagnosis requires three or more of the following five criteria:
- Waist circumference > 40 inches (men) or > 35 inches (women)
- Triglycerides ≥ 150 mg/dL or on treatment for elevated triglycerides
- HDL-C < 40 mg/dL (men) or < 50 mg/dL (women) or on treatment for low HDL
- Blood pressure ≥ 130/85 mmHg or on antihypertensive therapy
- Fasting glucose ≥ 100 mg/dL or on treatment for elevated glucose
Metabolic syndrome is present in approximately 35% of U.S. adults and is associated with a two- to three-fold increase in cardiovascular disease risk, independent of traditional risk factors. Its presence should prompt aggressive preventive evaluation — including ApoB, Lp(a), and consideration of CAC scoring.
Can Insulin Resistance Be Reversed?
Yes — and this is one of the most clinically meaningful areas of modern preventive cardiology. Unlike Lp(a) (genetically fixed) or age (immutable), insulin resistance is substantially modifiable through behavioral and pharmacological intervention.
Lifestyle interventions with strong evidence:
- Aerobic exercise — particularly Zone 2 training (sustained moderate intensity) — is the most potent tool for improving insulin sensitivity in skeletal muscle. Even 150 minutes per week of brisk walking produces measurable metabolic improvement.
- Resistance training increases muscle mass, which is the primary site of insulin-mediated glucose disposal and the largest reservoir for glycogen storage.
- Dietary carbohydrate quality — replacing refined carbohydrates and ultra-processed foods with vegetables, legumes, whole grains, and fiber significantly reduces insulin secretory demand.
- Weight loss, particularly loss of visceral fat (as opposed to subcutaneous fat), produces dramatic improvements in insulin sensitivity, triglycerides, HDL, and blood pressure simultaneously.
- Sleep — even a single night of severe sleep deprivation produces measurable insulin resistance. Chronic sleep disruption, including obstructive sleep apnea, is a significant and underappreciated driver of metabolic deterioration.
- Stress management — cortisol directly counteracts insulin signaling. Chronic psychological stress produces a low-grade cortisol elevation that contributes to insulin resistance and visceral fat accumulation.
Pharmacological options:
- Metformin — first-line pharmacotherapy for insulin resistance and prediabetes, with additional potential cardiovascular benefits beyond glucose lowering
- GLP-1 receptor agonists (semaglutide, liraglutide) — substantial insulin sensitization, weight loss, and now proven cardiovascular mortality reduction in high-risk patients
- SGLT-2 inhibitors (empagliflozin, dapagliflozin) — strong cardiovascular and renal outcome data, now used in patients with and without diabetes for heart failure and atherosclerotic cardiovascular disease reduction
- Pioglitazone — potent insulin sensitizer with evidence for carotid intima-media thickness regression in patients with insulin resistance; considered in select patients
What I Assess at ElinMed
Every new patient evaluation at ElinMed includes fasting insulin, HOMA-IR, and TG/HDL ratio as standard components of cardiometabolic assessment. Insulin resistance is not a diabetes diagnosis to wait for — it is a cardiovascular risk state to identify and address proactively. In patients with metabolic features, I expand the evaluation to full ApoB, NMR lipoproteins, and CAC scoring where appropriate.The gap between the cardiovascular impact of insulin resistance and the frequency with which it is identified and managed is one of the most consequential in preventive medicine. Tens of millions of Americans are accumulating arterial damage under the cover of "normal" labs. The tools to detect and reverse this process exist. The will to use them proactively is what separates preventive cardiology from reactive medicine.
Find Out If Insulin Resistance Is Driving Your Risk
A comprehensive metabolic and cardiovascular assessment at ElinMed goes beyond standard labs — measuring fasting insulin, ApoB, TG/HDL, and other markers that reveal what a standard panel hides.
Book a Visit